OA10745A - Isothiazolones - Google Patents

Isothiazolones Download PDF

Info

Publication number
OA10745A
OA10745A OA70126A OA70126A OA10745A OA 10745 A OA10745 A OA 10745A OA 70126 A OA70126 A OA 70126A OA 70126 A OA70126 A OA 70126A OA 10745 A OA10745 A OA 10745A
Authority
OA
OAPI
Prior art keywords
compound
alkyl
cr6r7
phenyl
employing
Prior art date
Application number
OA70126A
Other languages
English (en)
Inventor
Gary Louis Bolton
John Michael Domagala
Edwar Faith Elslager
Rocco Dean Gogliotti
Terri Stoeber Purchase
Joseph Peter Sanchez
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of OA10745A publication Critical patent/OA10745A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
OA70126A 1995-05-31 1997-11-12 Isothiazolones OA10745A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/456,149 US5620997A (en) 1995-05-31 1995-05-31 Isothiazolones

Publications (1)

Publication Number Publication Date
OA10745A true OA10745A (en) 2002-12-10

Family

ID=23811632

Family Applications (1)

Application Number Title Priority Date Filing Date
OA70126A OA10745A (en) 1995-05-31 1997-11-12 Isothiazolones

Country Status (37)

Country Link
US (4) US5620997A (xx)
EP (1) EP0828488B1 (xx)
JP (1) JP2002502353A (xx)
KR (2) KR19990022132A (xx)
CN (1) CN1114402C (xx)
AR (1) AR002740A1 (xx)
AT (1) ATE232385T1 (xx)
AU (1) AU723233B2 (xx)
BG (1) BG62792B1 (xx)
CA (1) CA2218253A1 (xx)
CO (1) CO4700292A1 (xx)
CZ (1) CZ373997A3 (xx)
DE (1) DE69626203T2 (xx)
DK (1) DK0828488T3 (xx)
EA (1) EA000898B1 (xx)
EE (1) EE9700287A (xx)
ES (1) ES2192224T3 (xx)
GE (1) GEP20012375B (xx)
GT (1) GT199600026A (xx)
HN (1) HN1996000017A (xx)
HR (1) HRP960216B1 (xx)
HU (1) HUP9900917A3 (xx)
IL (1) IL117859A (xx)
MX (1) MX9707948A (xx)
MY (1) MY118452A (xx)
NO (1) NO975496L (xx)
NZ (1) NZ307023A (xx)
OA (1) OA10745A (xx)
PE (1) PE55097A1 (xx)
PL (1) PL323683A1 (xx)
PT (1) PT828488E (xx)
SK (1) SK162297A3 (xx)
SV (2) SV1996000026A (xx)
TW (1) TW418206B (xx)
UY (1) UY24244A1 (xx)
WO (1) WO1996038144A1 (xx)
ZA (1) ZA964441B (xx)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001863A (en) * 1996-11-26 1999-12-14 Warner-Lambert Company Isothiazolones
US6706729B1 (en) 1998-06-19 2004-03-16 The United States Of America As Represented By The Department Of Health And Human Services Thiolesters and uses thereof
DE69932820T4 (de) * 1998-06-19 2008-06-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thiolester und ihre anwendungen
KR20010075150A (ko) 1998-09-17 2001-08-09 스티븐 비. 데이비스 ａＰ2 억제제 또는 조합을 사용하여 당뇨병을 치료하는 방법
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
TW591031B (en) * 2000-02-29 2004-06-11 Takeda Chemical Industries Ltd Thienopyridine derivatives, their production and use
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6432433B1 (en) 2000-06-05 2002-08-13 Isp Investments Inc. Liquid biocidal composition of a formaldehyde adduct and an isothiazolone and method of use
AU2001289749B9 (en) 2000-07-26 2004-08-19 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
EP1385856B1 (en) 2001-04-11 2006-02-22 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
PL377687A1 (pl) 2001-10-18 2006-02-06 Bristol-Myers Squibb Company Środki naśladujące ludzki peptyd glukagonopodobny typu 1 i ich zastosowanie w leczeniu cukrzycy i stanów związanych z cukrzycą
EP1443919A4 (en) 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
WO2003055448A2 (en) * 2001-12-21 2003-07-10 Achillion Pharmaceuticals, Inc. Antifungal compositions
US7101676B2 (en) * 2002-01-11 2006-09-05 Douglas Buechter Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA
EP2181996A1 (en) 2002-01-29 2010-05-05 Glaxo Group Limited Aminopiperidine derivatives
KR100653017B1 (ko) * 2002-02-08 2006-12-01 에프. 호프만-라 로슈 아게 골 손실의 치료 및 예방 방법
GB0208223D0 (en) * 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2004037181A2 (en) 2002-10-23 2004-05-06 Bristol-Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
NZ547752A (en) 2003-11-12 2009-12-24 Phenomix Corp Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2004312511A1 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Benzo(d)isoxazol-3-ol DAAO inhibitors
KR20060128976A (ko) * 2003-12-29 2006-12-14 세프라코 아이엔시. 피롤 및 피라졸 디에이에이오 억제제
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
WO2006017292A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
BRPI0611388A2 (pt) * 2005-05-04 2010-09-08 Hoffmann La Roche compostos antivirais heterocìclicos, uso dos mesmos e composição farmacêutica
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
CN101553217A (zh) 2005-07-06 2009-10-07 塞普拉科公司 艾司佐匹克隆与反式4－(3,4－二氯苯基)－1,2,3,4－四氢－n－甲基－1－萘胺或反式4－(3,4－二氯苯基)－1,2,3,4－四氢－1－萘胺的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法
US7488725B2 (en) 2005-10-31 2009-02-10 Bristol-Myers Squibb Co. Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
US7464565B2 (en) * 2005-11-29 2008-12-16 Maytag Corporation Rapid temperature change device for a refrigerator
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AU2006335174B2 (en) * 2006-01-06 2012-09-06 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
CA2636324C (en) 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
EP2013835B1 (en) 2006-03-31 2015-11-04 Sunovion Pharmaceuticals Inc. Preparation of chiral amides and amines
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2008057857A1 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
US20090099248A1 (en) * 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
JP2010526145A (ja) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー ［６，６］および［６，７］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
EP2152707B1 (en) 2007-05-04 2012-06-20 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
AU2008256937A1 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
EP2154962A4 (en) 2007-05-31 2012-08-15 Sepracor Inc PHENYL-SUBSTITUTED CYCLOALKYLAMINE AS A MONOAMINE RECOVERY INHIBITOR
PL2173737T3 (pl) 2007-07-17 2012-06-29 Bristol Myers Squibb Co Sposób modulowania receptora GPR119 sprzężonego z białkiem G i wybrane związki
WO2009018065A2 (en) 2007-07-27 2009-02-05 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
SI2187742T1 (en) 2007-08-23 2018-02-28 Theracos Sub, Llc DERIVATS (2S, 3R, 4R, 5S, 6R) -2- (4-CHLORO-3-BENZYLPHENYL) -6- (HYDROXYMETYL) TETRAHYDRO-2H-PIRAN-3,4,5-TRIOL FOR THE USE IN DIABETES TREATMENT
EP2209780B1 (en) 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
WO2009062288A1 (en) * 2007-11-15 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
ES2463720T3 (es) * 2007-11-16 2014-05-29 Gilead Sciences, Inc. Inhibidores de la replicación del virus de inmunodeficiencia humana
US9061060B2 (en) 2008-07-15 2015-06-23 Theracos Inc. Deuterated benzylbenzene derivatives and methods of use
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
SI2498758T1 (sl) 2009-11-13 2018-10-30 Astrazeneca Ab Formulacije dvoplastnih tablet
CA2780938A1 (en) 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Reduced mass metformin formulations
PL2498759T3 (pl) 2009-11-13 2019-03-29 Astrazeneca Ab Formulacje tabletek o natychmiastowym uwalnianiu
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US20110257233A1 (en) * 2010-03-19 2011-10-20 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
JP2013523822A (ja) 2010-04-08 2013-06-17 ブリストル−マイヤーズ スクイブ カンパニー Ｇｐｒ１１９修飾因子としてのピリミジニルピペリジニルオキシピリジノ類似体
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
EA201270778A1 (ru) 2010-05-06 2013-04-30 Бристол-Майерс Сквибб Компани Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2012018950A1 (en) 2010-08-03 2012-02-09 Beth Israel Deaconess Medical Center Methods and compositions for treatment of metabolic disorders
US9662328B2 (en) 2010-11-29 2017-05-30 National Yang-Ming University Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells
TWI445696B (zh) 2010-11-29 2014-07-21 Univ Nat Yang Ming 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的ｄｎａ修復毒性
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
EP2850073B1 (en) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
HUE043868T2 (hu) 2012-11-20 2019-09-30 Lexicon Pharmaceuticals Inc Nátrium-glükóz kotranszporter 1 inhibitorai
CN103232842B (zh) * 2013-04-15 2015-11-18 山东大学 一种基于聚集诱导荧光增强材料的亚硫酸氢根离子的荧光探针及快速检验试纸
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US20160046651A1 (en) * 2014-07-22 2016-02-18 Washington University Treatment of malaria using inhibitors of the ispd enzyme in the non-mevalonate pathway
CN104230839A (zh) * 2014-09-25 2014-12-24 上海化学试剂研究所有限公司 一种n-取代苯并异噻唑啉酮衍生物的合成方法
US9925190B2 (en) * 2015-02-16 2018-03-27 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting HIV-1 Nef
KR20170138570A (ko) 2015-04-30 2017-12-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
WO2018017910A1 (en) 2016-07-22 2018-01-25 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
CN111518770B (zh) 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
WO2019126567A1 (en) * 2017-12-22 2019-06-27 Southern Research Institute Substituted heterocyclic-pyridinones as hiv-1 nef-hck inhibitors
JP7472139B2 (ja) 2018-08-23 2024-04-22 チンタオ、ライジング、バイオテクノロジー、カンパニー、リミテッド フェノキシカルボン酸化合物およびその医薬用途
SG11202102498UA (en) 2018-09-26 2021-04-29 Lexicon Pharmaceuticals Inc Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
CN111253335B (zh) * 2020-03-12 2023-06-06 浙江扬帆新材料股份有限公司 一种n-取代苯并异噻唑啉-3-酮衍生物的新合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE724034C (de) * 1938-11-04 1942-08-17 Algemeene Kunstvezel Mij N V Verfahren zum Erzeugen farbiger Glasfasern
US3012039A (en) * 1958-03-14 1961-12-05 Ici Ltd 2-p-chlorobenzyl-1, 2-benzisothiazolone
US3517022A (en) * 1967-10-03 1970-06-23 Rohm & Haas Certain 2-carbamoyl-1,2-benzisothiazolones
GB1306493A (en) * 1970-04-27 1973-02-14 Sherwin Williams Co Aromatic sulphenamides the preparation thereof and cyclization thereof
US3661974A (en) * 1970-04-27 1972-05-09 Sherwin Williams Co 2-carbalkoxy-phenyl sulfenamides
US3761489A (en) * 1971-12-20 1973-09-25 Sherwin Williams Co Substituted n-alkyl benzisothiazolinones
US4049817A (en) * 1972-08-14 1977-09-20 Sandoz Ltd. Synergistic compositions
US3965107A (en) * 1974-07-08 1976-06-22 Rohm And Haas Company Isothiazolopyridinones
IT1039699B (it) * 1975-07-03 1979-12-10 Prephar Composizione spermicida a base di derivati benzisotiazolici
DE2602643C2 (de) * 1976-01-24 1984-12-20 Bayer Ag, 5090 Leverkusen 1,2-Benzisothiazolinone-3, Verfahren zu ihrer Herstellung sowie Arzneimittel
GB1560726A (en) * 1976-04-28 1980-02-06 Beecham Group Ltd Isothiazolo-pyridines
FR2492376A1 (fr) * 1980-10-17 1982-04-23 Cird Polymethylene-4,5 isothiazoline-4 ones-3, leur procede de preparation et leurs utilisation comme agents bactericides et fongicides
DE3041036A1 (de) * 1980-10-31 1982-06-09 A. Nattermann & Cie GmbH, 5000 Köln Verwendung von benzisothiazolen
US4458942A (en) * 1981-12-07 1984-07-10 American Seating Company Three-quarter fold retracting chair
LU84091A1 (fr) * 1982-04-16 1984-03-02 Oreal Derives n-carbamoyl d'isothiazolo-(5,4b)pyridine one-3,leur procede de preparation et leurs utilisations comme agents bactericides et fongicides
FR2555450B1 (fr) * 1983-11-24 1988-04-01 Oreal Composition anti-acneique contenant en tant que compose actif un derive d'isothiazolo-(5,4b) pyridine one-3
FR2631028B1 (fr) * 1988-05-09 1990-07-13 Cird Adamantyl-2 isothiazoline-4 ones-3, leur procede de preparation et leur utilisation comme agents bactericides et fongicides
US5405851A (en) * 1990-06-19 1995-04-11 Burroughs Wellcome Co. Pharmaceutical compounds
JPH0477476A (ja) * 1990-07-19 1992-03-11 Sankyo Co Ltd 抗潰瘍剤
US5219875A (en) * 1990-11-27 1993-06-15 Rohm And Haas Company Antimicrobial compositions comprising iodopropargyl butylcarbamate and 1,2-benzisothiazolin-3-one and methods of controlling microbes
NO304832B1 (no) * 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
FR2695378B1 (fr) * 1992-09-10 1994-12-02 Aerospatiale Dispositif à sangle pour le maintien temporaire d'objets ensemble.
RU2118322C1 (ru) * 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли

Also Published As

Publication number Publication date
ZA964441B (en) 1996-12-10
KR19990022132A (ko) 1999-03-25
CN1185737A (zh) 1998-06-24
PL323683A1 (en) 1998-04-14
JP2002502353A (ja) 2002-01-22
DE69626203D1 (en) 2003-03-20
UY24244A1 (es) 2001-10-25
MY118452A (en) 2004-11-30
US5620997A (en) 1997-04-15
ES2192224T3 (es) 2003-10-01
EP0828488B1 (en) 2003-02-12
HRP960216B1 (en) 2001-12-31
KR20040004547A (ko) 2004-01-13
US5733921A (en) 1998-03-31
IL117859A (en) 2000-07-16
HUP9900917A2 (hu) 1999-09-28
SV1996000033A (es) 1998-01-29
DE69626203T2 (de) 2003-11-20
NO975496D0 (no) 1997-11-28
DK0828488T3 (da) 2003-05-19
CN1114402C (zh) 2003-07-16
PT828488E (pt) 2003-06-30
WO1996038144A1 (en) 1996-12-05
EA199700444A1 (ru) 1998-06-25
ATE232385T1 (de) 2003-02-15
NZ307023A (en) 2001-03-30
CZ373997A3 (cs) 1998-11-11
PE55097A1 (es) 1998-01-16
GT199600026A (es) 1997-11-15
US5668162A (en) 1997-09-16
EE9700287A (et) 1998-06-15
AR002740A1 (es) 1998-04-29
MX9707948A (es) 1997-12-31
SK162297A3 (en) 2000-04-10
BG62792B1 (bg) 2000-08-31
TW418206B (en) 2001-01-11
US6133270A (en) 2000-10-17
HN1996000017A (es) 2000-03-24
CO4700292A1 (es) 1998-12-29
IL117859A0 (en) 1996-08-04
EP0828488A1 (en) 1998-03-18
GEP20012375B (en) 2001-03-25
NO975496L (no) 1998-01-22
HRP960216A2 (en) 1997-08-31
AU5577196A (en) 1996-12-18
BG102077A (en) 1998-11-30
HUP9900917A3 (en) 2003-04-28
EA000898B1 (ru) 2000-06-26
CA2218253A1 (en) 1996-12-05
SV1996000026A (es) 1997-03-05
AU723233B2 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
OA10745A (en) Isothiazolones
AU711438B2 (en) 7-amino-1H-indol derivatives
RO119193B1 (ro) Derivaţi de ariltiol şi compoziţie farmaceutică
SK285571B6 (sk) 8,8a-Dihydroindeno[1,2-d]tiazolové deriváty nesúce v polohe 2 substituent so sulfónamidovou štruktúrou, spôsob ich prípravy a farmaceutické prostriedky, ktoré ich obsahujú
EP0700911B1 (en) Imidazole derivatives having anti-HIV activity
WO2005019191A2 (en) 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
ES2207277T3 (es) Compuestos utiles como inhibidores de aircraft.
AU626541B2 (en) Anti-tumour agents
KR100203234B1 (ko) 하이드라존, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR20020002394A (ko) 비만증 예방 또는 치료용 약제를 제조하기 위한,폴리사이클릭 2-아미노-티아졸계의 용도
CA2091688A1 (en) Antiproliferative substituted naphthalene compounds
US5889034A (en) Isothiazolones
AU598285B2 (en) Diselenobis benzoic acid amides of primary heterocyclic amines, process for producing the same and pharmaceutical compounds comprising the same
US10815207B2 (en) Substituted hydrophobic benzene sulfonamide thiazole compounds for use in treating cancer
AU777036B2 (en) Thiazepine inhibitors of HIV-1 integrase
BRPI0710843A2 (pt) tiazolil-di-hidro-indazóis
JPS62148490A (ja) １−Ｈ−ピリド−〔３，２−ｂ〕〔１，４〕−チアジン